A detailed history of Advisor Group Holdings, Inc. transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 32,593 shares of ATXS stock, worth $311,589. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32,593
Previous 32,457 0.42%
Holding current value
$311,589
Previous $295,000 21.36%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$8.97 - $12.65 $1,219 - $1,720
136 Added 0.42%
32,593 $358,000
Q2 2024

Aug 13, 2024

BUY
$8.83 - $13.51 $1,713 - $2,620
194 Added 0.6%
32,457 $295,000
Q1 2024

May 10, 2024

BUY
$6.99 - $16.69 $221,589 - $529,089
31,701 Added 5640.75%
32,263 $453,000
Q1 2023

May 12, 2023

BUY
$11.2 - $15.79 $6,294 - $8,873
562 New
562 $7,000
Q1 2022

May 04, 2022

SELL
$3.92 - $7.1 $364 - $660
-93 Closed
0 $0
Q3 2021

Nov 05, 2021

BUY
$7.32 - $12.9 $680 - $1,199
93 New
93 $1,000

Others Institutions Holding ATXS

About Astria Therapeutics, Inc.


  • Ticker ATXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,178,000
  • Market Cap $145M
  • Description
  • Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...
More about ATXS
Track This Portfolio

Track Advisor Group Holdings, Inc. Portfolio

Follow Advisor Group Holdings, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.